Jane Street
VOR icon

Jane Street’s Vor Biopharma VOR Stock Holding History

Jane Street’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,225
Closed -$173K – 13112
2025
Q4 		$173K Sell
13,225
-8,095
-38% -$151K ﹤0.01% 9843
2025
Q3 		$1.04M Sell
21,320
-8,190
-28% -$329K ﹤0.01% 6238
2025
Q2 		$956K Buy
+29,510
New +$261K ﹤0.01% 5701

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Jane Street's VOR Position: Q2 2026 in Review

Jane Street sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 75,890 shares — an estimated $1.35M sold.

Jane Street first reported a position in VOR in Q3 2022 and held it in 13 quarters. The position peaked at $1.35M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Jane Street reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 75,890 Vor Biopharma shares in Q2 2026, an estimated $1.35M.
  • Jane Street first reported a position in Vor Biopharma in Q3 2022 and held it in 13 quarters.
  • Jane Street's Vor Biopharma position peaked at $1.35M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.